Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Family with sequence similarity 133 member A (FAM133A)
- Target
- FAM133A
- Molecular classification
- Other (protein-coding gene; not a receptor, enzyme, transporter, channel, or transcription factor)
01
Overview
Family with sequence similarity 133 member A (FAM133A) is a protein-coding gene expressed in various tissues and implicated in diverse biological processes. It is involved in neuronal function (with evidence of regulation by catechol-O-methyltransferase genotype), shows significant correlations with cancer development and progression (notably in pancreatic adenocarcinoma and thyroid cancer), and has been suggested as a marker within immune response models in cervical cancer. Genetic association data further link FAM133A to metabolic traits such as fasting insulin levels, potentially intersecting with diabetes pathophysiology. Though FAM133A is associated with disease prognosis and biological regulation, it is not currently accepted as a classic druggable target (receptor, enzyme, etc.), and its direct molecular function remains to be fully elucidated
- Other names
- CT115Cancer/testis antigen 115Protein FAM133ARP1-32F7.2FLJ37659
02
Mechanism of action
Not established. No drugs currently target FAM133A directly
03
Biological functions
Neuronal function regulation and possible modulation of estrogen‐responsive genesImplicated in cancer metastasis and tumorigenesis (co-expression network in pancreatic adenocarcinoma)Metabolic regulation connected with fasting insulin levelsPossible roles in immune microenvironment and biomarker potential for immune status in cancer
04
Disease associations
Cancer (implicated in pancreatic adenocarcinoma, papillary thyroid cancer, cervical cancer)Metabolic disease (association with fasting insulin regulation, suggesting a connection to type 2 diabetes pathophysiology)
05
Safety considerations
None known. No therapeutic interventions targeting FAM133A have been reported, therefore safety profile as a drug target is undetermined
06
Interacting drugs
None established. There are associations with gene expression changes after drug perturbation, but no direct evidence for drugs that interact specifically with FAM133A
07
Biomarkers
Potential biomarker in cancer, especially within immune gene–related prognostic models for cervical cancer and as a hub gene in pancreatic adenocarcinoma metastasis
Beyond the preview
Go deeper on Family with sequence similarity 133 member A (FAM133A).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Family with sequence similarity 133 member A (FAM133A).